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Background: Preterm birth (PTB) is a complex disorder associated with significant neonatal mortality and morbidity
and long-term adverse health consequences. Multiple lines of evidence suggest that genetic factors play an
important role in its etiology. This study was designed to identify genetic variation associated with PTB in oxytocin
pathway genes whose role in parturition is well known.
Methods: To identify common genetic variants predisposing to PTB, we genotyped 16 single nucleotide
polymorphisms (SNPs) in the oxytocin (OXT), oxytocin receptor (OXTR), and leucyl/cystinyl aminopeptidase (LNPEP)
genes in 651 case infants from the U.S. and one or both of their parents. In addition, we examined the role of rare
genetic variation in susceptibility to PTB by conducting direct sequence analysis of OXTR in 1394 cases and 1112
controls from the U.S., Argentina, Denmark, and Finland. This study was further extended to maternal triads
(maternal grandparents-mother of a case infant, N=309). We also performed in vitro analysis of selected rare OXTR
missense variants to evaluate their functional importance.
Results: Maternal genetic effect analysis of the SNP genotype data revealed four SNPs in LNPEP that show
significant association with prematurity. In our case–control sequence analysis, we detected fourteen coding
variants in exon 3 of OXTR, all but four of which were found in cases only. Of the fourteen variants, three were
previously unreported novel rare variants. When the sequence data from the maternal triads were analyzed using
the transmission disequilibrium test, two common missense SNPs (rs4686302 and rs237902) in OXTR showed
suggestive association for three gestational age subgroups. In vitro functional assays showed a significant difference
in ligand binding between wild-type and two mutant receptors.
Conclusions: Our study suggests an association between maternal common polymorphisms in LNPEP and
susceptibility to PTB. Maternal OXTR missense SNPs rs4686302 and rs237902 may have gestational age-dependent
effects on prematurity. Most of the OXTR rare variants identified do not appear to significantly contribute to the risk
of PTB, but those shown to affect receptor function in our in vitro study warrant further investigation. Future studies
with larger sample sizes are needed to confirm the findings of this study.
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Preterm birth (PTB) is a major public health problem
that accounts for approximately 10% of all births world-
wide [1,2]. In 2011, PTBs, occurring before 37 com-
pleted weeks of gestation, comprised 11.73% of live
births in the United States [3]. Prematurity is a leading
cause of perinatal mortality and in survivors is a signifi-
cant contributor to short- and long-term morbidity [4].
The etiology of PTB is not completely understood, but
multiple lines of evidence suggest that genetic factors
play an important role in PTB, including a high rate of
recurrence in individuals with a history of previous pre-
term delivery (PTD), a tendency to occur within fam-
ilies, and racial disparity [1,5-7].
The oxytocin (OXT)-oxytocin receptor (OXTR) sys-
tem provides promising candidate genes for studies of
genetic contributions to prematurity. Its components in-
fluence a wide range of physiological, behavioral, and
emotional processes in humans, but have been most ex-
tensively studied for their role in reproduction, particu-
larly labor and parturition [8,9]. OXT acts as an inducer
of uterine contraction and the myometrium becomes in-
creasingly sensitive to the action of OXT towards term
[8]. This increase in uterine sensitivity to OXT occurs
concomitantly with an upregulation of OXTR mRNA
and a dramatic increase in myometrial OXTR number,
which peaks during early labor [8,9]. The OXTR is a G
protein-coupled receptor, which, upon stimulation, acti-
vates various intracellular signaling pathways such as the
phosphoinositide cascade, eventually leading to uterine
contraction [8,10,11]. The availability of OXT to the re-
ceptor is dependent on serum levels of leucyl/cystinyl
aminopeptidase (LNPEP), an enzyme that hydrolyzes
and inactivates the hormone [12,13]. LNPEP, also known
as PLAP, increases in maternal serum during pregnancy
and plays an important role in fetal development as well
as pregnancy maintenance via regulating OXT levels and
activity [12,13]. The efficacy of Atosiban, an OXT antag-
onist used to stop premature uterine contractions and
delay PTD [14], provides further support for the import-
ance of this hormonal system in prematurity.
Previous candidate gene association studies have pro-
vided evidence for genetic variation predisposing to
PTB with four maternal and one fetal variants showing
relatively consistent evidence of association [15]. In the
present study, we hypothesize that allelic variations in
OXT, OXTR, and LNPEP contribute to the genetic pre-
disposition to prematurity. We evaluated the association
between maternal and fetal genotypes of single nucleo-
tide polymorphisms (SNPs) in the three genes and PTD
in U.S. patients. We also performed direct sequence
analysis in four population groups to search for rare
variants in the OXT-OXTR system (particularly in the
OXTR gene) that might play a role in PTB. Selected rareOXTR variants identified in preterm cases were then
further investigated to determine their functional
significance.
Methods
Study population
The study population consisted of case and control pa-
tients from 4 countries, including the U.S. (4 sites; the
University of Iowa Hospitals and Clinics in Iowa City, IA,
Magee-Womens Hospital in Pittsburgh, PA, University
of Rochester Medical Center in Rochester, NY, and
Wake Forest University in Wake Forest, NC), Argentina
(two centers; Instituto de Maternidad y Ginecología
Nuestra Señora de las Mercedes in Tucumán and Hospital
Provincial de Rosario in Rosario), Finland (the University
of Helsinki in Helsinki), and Denmark (the island of Funen
and the Danish National Birth Cohort (DNBC) [16]). All
families provided signed informed consent for study en-
rollment in accordance with the protocols approved by
research ethics committees in the U.S. (the University
of Iowa Institutional Review Board (IRB), University of
Pittsburgh IRB, University of Rochester Research Sub-
jects Review Board, Wake Forest University Health Sci-
ences IRB), Argentina (the Research Ethics Committee of
Centro de Educación Médica e Investigaciones Clínicas),
Finland (the Ethics Committee of the University Central
Hospital, Helsinki), and Denmark (the Scientific-Ethical
Committee of the Southern Danish Region and the Bio-
medical Research Ethics Committee of the Capital City
Region of Denmark). PTD was defined as delivery before
37 completed weeks of gestation. Gestational age (GA)
was determined by obstetrical assignment using the first
day of the last menstrual period as well as ultrasound
examination, and was confirmed by assessment at birth.
Demographic and clinical data were collected by chart re-
view and/or clinician interview. Table 1 summarizes
demographic characteristics of each population studied.
U.S. cases were families with either a spontaneous or med-
ically indicated preterm birth - of note, twin births were
excluded at the data analysis step. Cases from Finland
(mother-infant dyads, <36 weeks’ gestation) were families
with spontaneous onset of preterm singleton birth from
2003 to 2009, selected using the following exclusion cri-
teria: elective deliveries without spontaneous onset of
labor and deliveries in which either maternal (e.g. systemic
infection) or fetal (e.g. malformation) disease with known
predisposition to premature birth was indicated. Finnish
control families were defined as those with two or more
children, all of whom were delivered at 37 weeks or later.
The median gestational ages for index mother-infant
dyads were 34 and 40 weeks for cases and controls, re-
spectively. Danish cases and controls were identified on
Funen where the University Hospital of Odense was a
major participating site for case collection, and from the
Table 1 Demographic characteristics of study populations
SNP
genotyping
Resequencing
Case-control3 Maternal triad4
U.S. Argentina Denmark U.S. Argentina U.S.
N=651 Case (N=123) Control (N=63) P Case (N=723) Control
(N=920)
P Case (N=443) Control (N=34) P N=187 N=109
GA (weeks)1 31.1 ± 3.7
(21–36)
33.1 ± 2.5
(27–36)
39.4 ± 0.9
(37–41)
* 33.7 ± 2.8
(20–36)
40 N/A 30.3 ± 3.8
(22–36)
38.9 ± 1.1
(37–41)
* 32.6 ± 3.0
(23–36)
32.0 ± 3.8
(24–36)
[Unknown: 5]
Infant BW (grams)1 1739.4 ± 814.7
(332–4610)
1834.8 ± 514
(830–3200)
3514.1 ± 487
(2430–4950)
* 2444 ± 648
(250–5270)
3720.7 ± 457
(2400–5250)
* 1606 ± 791
(332–4400)
3495.2 ± 417.9
(2380–4275)
* 1763.3 ± 527.2
(615–3040)
1967.5 ± 778.2
(597–3691)
[Unknown: 5]
Infant gender
(male/female)2
373/278 65/57 31/32 0.64 385/338 482/438 0.77 249/194 20/14 0.85 99/87 54/55
[Unknown: 1]
Maternal age at
delivery (years)1
27.8 ± 6.2
(14–46)
24.7 ± 6.5
(15–48)
26.0 ± 6.1
(16–40)
0.22 29.1 ± 4.4
(17–44)
29.7 ± 4.0
(18–42)
0.001 27.7 ± 6.0
(14–44)
27.9 ± 5.3
(18–40)
0.86 23.2 ± 5.3
(16–39)
30.3 ± 5.2
(18–41)
[Unknown: 15] [Unknown: 3] [Unknown: 11]
1Data are presented as mean ± standard deviation, with range in parenthesis.
2Data are presented as counts.
3Resequencing was also performed on Finnish cases (N=105) and controls (N=95). See the Methods section for a demographic description of this population.
4Data for Danish maternal triads (N=13) are not shown.
* <0.0001.
GA: gestational age, BW: birth weight, N/A: not available.
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Table 2 List of SNPs in the OXT, OXTR, and LNPEP genes
genotyped
Gene SNP Alleles Chr Position1 MAF
OXT rs2740210 G/T 20 3053255 0.32
OXTR rs7632287 A/G 3 8791446 0.25
rs11706648 A/C 3 8796547 0.33
rs237887 A/G 3 8797042 0.41
rs4686301 C/T 3 8798586 0.29
rs237889 C/T 3 8802483 0.37
rs53576 A/G 3 8804371 0.32
rs237893 A/G 3 8805950 0.42
rs237897 A/G 3 8808285 0.36
rs4686302 C/T 3 8809222 0.12
LNPEP rs4869315 A/G 5 96229272 0.44
rs3849749 A/T 5 96234533 0.41
rs4869317 A/T 5 96292004 0.28
rs18059 C/T 5 96352068 0.48
rs316206 C/T 5 96380733 0.32
rs13175726 A/G 5 96387033 0.29
1Position according to NCBI Build 37.3 GRCh37.p5 assembly.
SNP: single nucleotide polymorphism, Chr: chromosome, MAF: minor
allele frequency.
Kim et al. BMC Medical Genetics 2013, 14:77 Page 4 of 14
http://www.biomedcentral.com/1471-2350/14/77DNBC [16]. The DNBC consisted of 96,946 total births, in-
cluding 5,352 preterm births, occurring between 1997 and
2002. We selected 723 case (≤36 weeks gestation) and 920
control (40 weeks gestation) mothers for our study. Individ-
uals were considered for inclusion in this study only if there
was no evidence of obstetrical induction, placental ab-
normalities, pre-eclampsia, congenital malformations, and
multiple births. Biological samples collected from mothers
were stored in the Biobank at Statens Serum Institut in
Copenhagen. Epidemiologic information was collected
from existing medical records and from three maternal in-
terviews, during the first trimester, at about 30 weeks gesta-
tion and 6 months after birth.
SNP genotyping
A total of 812 premature infants born in Iowa between
1999 and 2008 with GAs between 21 and 36 weeks (mean,
31 ± 3.7 weeks) and one or both of their parents were se-
lected for genotyping. DNA was extracted from cord
blood or discarded venous blood from the infants and
venous blood, buccal swab, or saliva from the parents
using standard protocols. Genotyping for SNP markers
was performed using TaqMan assays (Applied Biosystems,
Foster City, CA, U.S.) as described in detail elsewhere
[17]. A total of 16 tagging SNPs were selected to cover
haplotype blocks of the oxytocin gene (OXT; 1 SNP), the
oxytocin receptor gene (OXTR; 9 SNPs), and the leucyl/
cystinyl aminopeptidase gene (LNPEP; 6 SNPs). The SNPs
genotyped, along with their minor allele frequencies
(MAFs), are listed in Table 2. Twin births were excluded,
leaving 651 singleton infants for analysis. Of the 651 in-
fants, 565 were successfully genotyped with GAs between
23 and 36 weeks (mean 31.1 ± 3.75).
Sequencing
A subgroup of the genotyped Iowa patients was selected
for phase 1 sequencing based on GA, including 94 infants
and 95 mothers of different infants with GA between 24–
32 weeks. All three coding exons of OXT and all four
exons of OXTR were sequenced in both directions, as de-
scribed in prior studies [17]. Phase 2 (replication) sequen-
cing, where we focused only on exon 3 of OXTR, was
performed on cases and controls from Argentina (infants
and mothers; case, N=212 and control, N=125), Denmark
(mothers participating in the DNBC; case, N=723 and
control, N=920), Finland (mothers; case, N=105 and con-
trol, N=95), and the U.S. (infants and mothers; case,
N=719 and control, N=229). Removal of twin births as
well as unsuccessfully genotyped individuals left a very
small number of Argentinian and U.S. controls, making
a case–control association analysis particularly for the
Argentinian population impossible.
To assess the effect of maternal OXTR genotype on
the risk of PTD, we performed sequence analysis on thesame region of OXTR in maternal triads (each including
a mother of a premature infant with GA between 23 and
36 weeks (single gestation, born after spontaneous onset
of labor) and her parents) as well as in a small group of
patients consisting of 71 case and 64 control mothers.
These case and control mothers were all Caucasians
from Iowa with a singleton spontaneous delivery be-
tween 2005 and 2010. Further exclusion criteria for cases
include preeclampsia and induction of labor. Of the 71
cases (mothers of preterm infants with GA between 23–
28 weeks and birth weight (BW) between 413 and 1770
grams) and the 64 controls (mothers of term infants
with GA between 39–42 weeks and BW between 2050
and 4756 grams), 62 cases and 60 controls with
complete data were included in the analysis. The mater-
nal grandmother-grandfather-mother triads were created
from 309 pedigrees from different populations, including
Argentina (2 centers, N=187), Denmark (the island of
Funen, N=13), and the U.S. (4 sites, N=109). The fam-
ilies were enrolled in the study between 2005 and 2010
(Argentina and U.S.) and between 2008 and 2009
(Denmark). Of note, the small sample size of the Danish
group (N=13) made statistical analysis uninformative. DNA
was extracted from venous blood or saliva (Argentina),
saliva (Denmark), and venous blood, buccal swab, or
saliva (U.S.) and subsequently used for sequencing. All
sequencing was performed by Functional Biosciences,
Inc., Madison, WI, U.S.
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A full-length cDNA encoding human OXTR [GenBank:
AY389507] was obtained from the Missouri S&T cDNA
Resource Center (Rolla, MO, U.S.). Site-directed muta-
genesis was performed to generate mutant constructs
possessing missense mutations of potential functional
significance identified in premature cases, including
P108A, W203R, and F284. The mutations were intro-
duced individually into the wild-type OXTR sequence
using a PCR-based mutagenesis strategy. The wild-type
and mutant full-length cDNAs were inserted into the
EcoRI and XhoI sites of expression vector pcDNA3.1 (+)
(Invitrogen, Carlsbad, CA, U.S.). The sequence of all
constructs was confirmed by sequencing.
African green monkey kidney COS-7 cells were main-
tained in Dulbecco’s Modified Eagle’s Medium sup-
plemented with 10% newborn calf serum, 50 μg/mL
gentamicin, and 10 mM HEPES, pH 7.4. Cells were plated
at a density of 4 x 105 cells/well in 6-well (35-mm) plates,
and transiently transfected with plasmid DNA using
FuGENE® HD Transfection Reagent (Roche Applied Sci-
ence, Indianapolis, IN, U.S.) according to the manufac-
turer’s instructions. After overnight incubation, the cells
were washed and used in subsequent experiments.
Inositol phosphate assays
The accumulation of inositol phosphates was measured
using [3H]inositol-labeled cells incubated in the absence
or presence of 100 nM oxytocin for 1 h as described
elsewhere [18]. Results were presented as mean fold dif-
ference between stimulated and unstimulated values (in
cpm/106 cells) or mean ratio of the basal level in each
transfection group to that in the wild-type group.
Ligand binding assays
Two days after transfection, cells were washed twice
with warm buffer (20 mM HEPES, 0.15 M NaCl, 1 mg/
ml bovine serum albumin, pH 7.4), and incubated with
50 nM [3H]oxytocin (PerkinElmer, Waltham, MA, U.S.)
alone (total binding) or together with 20 μM unlabeled
oxytocin (nonspecific binding). After 2.5 hours of incu-
bation at room temperature, the cells were washed twice
with cold buffer and dissolved in 0.5 ml of 0.5 N NaOH
overnight. After collecting the lysate, each well was
washed with another 0.5 ml of 0.5 N NaOH, and the
wash was combined with the lysate, followed by
neutralization with 0.25 ml of 2 N HCl prior to measur-
ing radioactivity. Specific binding was determined by
calculating the difference between total and nonspecific
binding and was expressed as mean cpm/106 cells.
Statistical analysis
The common SNP genotyping data were tested for geno-
type deviation from the Hardy–Weinberg equilibrium(HWE) using PLINK [19] and Haploview [20]. We first
analyzed the data for all GAs together and then
performed stratified analyses. For both maternal and
fetal effects, five-week sliding windows of GA were uti-
lized, starting with 21–25 weeks and ending with 32–36
weeks. For fetal effect analysis, three-stage stratification
was additionally used, resulting in three GA groups:
early (between 21 and 27 weeks), middle (between 28
and 30 weeks), and late (between 31 and 36 weeks). We
performed a transmission disequilibrium test (TDT)
using the Family Based Association Test (FBAT) soft-
ware [21,22], which analyzes overtransmission of alleles
to an affected fetus [23]. For maternal genetic effect ana-
lysis, we used a log-linear approach to study maternally-
mediated effects [24]. This approach uses a case-parents
triad as the analysis unit and it tests maternally-mediated
genetic effects based on the symmetry assumption of al-
lele counts between the mothers and the fathers in the
source population [25]. We performed likelihood ratio
tests of the maternal genetic effects. The expectation-
maximization algorithm was applied to fully utilize fam-
ilies with missing parental genotypes [26]. We also
performed a haplotype analysis for all the six SNPs in
the LNPEP gene using TRIMM [27]. The test statistics
was constructed based on the vector of genotype differ-
ences between the mother and the father. Under genetic
mating symmetry assumption, the difference vector has
an expected value of 0 at each locus under the null hy-
pothesis. A permutation test was used to evaluate the
significance of the test statistic.
The sequencing data from the maternal triads were
analyzed in a similar way except that we defined as af-
fected those (mothers) who delivered preterm infants
and used GA and BW of the infants as phenotypes of
the case mothers. We performed a TDT using the FBAT
program [21,22] for each common or rare variant found
in the sequenced region. The data were analyzed for all
GAs together as well as for GA subgroups using five-
week sliding windows of GA and three-stage (early, mid-
dle, and late) stratification as described above.
We performed chi-square and Fisher’s exact tests
using SAS version 9.2 statistical program (SAS, Cary,
NC, U.S.) for a 2 by 2 or 2 by 3 contingency table to
analyze the sequence data on rare and common OXTR
variants found in cases and controls from Argentina,
Denmark, Finland, and the U.S. as well as a small group
of Caucasian case and control mothers from Iowa. In
the Iowa case and control study, we restricted our ana-
lysis to only 3 common polymorphisms (rs4686302,
rs237902, and rs61740241) because of the absence of
rare variant minor alleles in both cases and controls.
The Danish sequencing data were further analyzed
using linear regression to model genetic effects of the
OXTR variants identified on GA. In the Iowa case–
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to predict case/control status and linear regression ana-
lyses to predict GA (weeks) and BW (grams) on the
aforementioned three OXTR polymorphisms.
Data for inositol phosphate and ligand binding assays
were analyzed using one-way ANOVA, followed by
Dunnett's test with InStat software (GraphPad, La Jolla,
CA, U.S.).
Analysis of genetic variation in OXTR using publicly
available reference data
The OXTR sequencing results from our study were add-
itionally analyzed utilizing publicly available data from
two databases: 1) the 1000 Genomes Project (1000GP)
[28,29], which provides a catalogue of genetic variants
present in the genomes of healthy individuals from dif-
ferent ethnic groups, and 2) the National Heart, Lung,
and Blood Institute (NHLBI) Grand Opportunity (GO)
Exome Sequencing Project (ESP) [30], which provides a
catalogue of exome variants present in the genomes of ap-
proximately 2500 European and African American indi-
viduals from cohorts sampled for heart, lung, and blood
diseases . No data on these for GA is reported. We investi-
gated the two databases in search of coding variants in
exon 3 of the OXTR gene in European Americans and
African Americans, and then compared the variants re-
trieved with those identified in our sequencing study. The
variants reported in the 1000GP (February 2012 release,
20120316) [28,29] were annotated using the SeattleSeq
Annotation Server [31].
Results
Effects of common polymorphisms in the OXT pathway
genes on risk of PTB
We selected 16 SNPs in the OXT, OXTR, and LNPEP
genes based on haplotype block structures and examinedFigure 1 Results of fetal genetic effect analysis. No statistically significa
OXTR, and LNPEP genes and preterm birth risk either when all GAs togethe
window (B) stratification was used.them for their association with PTB in patients from the
U.S. (Iowa). All SNPs tested had a MAF greater than
10% (Table 2). Excluding one SNP (rs237889) with HWE
violation (p=8 x 10-5) and one SNP (rs4686302) with in-
sufficient informative families (n<10) left a total of 14
SNPs for analysis.Fetal genetic effects
Figure 1 shows the p-values obtained from fetal effect
analysis, using the entire set of data as well as subsets
classified by GA. There was no significant SNP found
either when all GAs were examined together (Figure 1A)
or when the GA-stratified analyses were performed
(Figure 1A and 1B).Maternal genetic effects
Figure 2 summarizes the results from the analysis of
maternally mediated genetic effects. When the analysis
was performed on all GA cases (Figure 2A), three SNPs
in LNPEP were found to have a p-value of less than 0.05
(rs4869315, p=0.035; rs3849749, p=0.019; rs4869317,
p=0.006). These values are uncorrected for the multiple
comparisons done in this study where a Bonferroni
corrected p-value for significance would be <0.002 ac-
counting for 14 SNPs and both maternal and fetal com-
parisons. When the analysis was stratified by GA using
five-week sliding windows (Figure 2B), the same vari-
ants in LNPEP remained significant - rs4869315 for the
30–34 (p=0.019) and 32–36 (p=0.009) week GA groups,
rs3849749 for the 32–36 (p=0.016) week GA group, and
rs4869317 for the 31–35 (p=0.024) and 32–36 (p=0.012)
week GA groups. Another LNPEP SNP, rs13175726
(p=0.035) was additionally found to be significant for
the 26–30 week GA group. Haplotype analysis of all 6
SNPs in LNPEP failed to yield any significant results.nt (p<0.05) association was found between any of the SNPs in the OXT,
r were evaluated (A) or when three-stage (A) or five-week sliding
Figure 2 Results of maternal genetic effect analysis. Three SNPs (rs4869315, rs3849749, rs4869317) in the LNPEP gene were significantly
associated with preterm birth when all GAs were together considered (A). Another SNP (rs13175726) in LNPEP as well as the same three SNPs
were found to be significant for several GA subgroups (B).
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association with PTB
Rare sequence variations in OXTR: phase 1 and phase 2
case–control resequencing studies
Lack of association between common polymorphisms in
OXT and OXTR led us to examine whether there exist
(s) rare genetic variant(s) in these two genes with poten-
tial effects on the risk of prematurity. To this end, we
first sequenced all exons of OXT and OXTR in a sub-
group (n=189) of the genotyped (U.S.) patients. This
pilot (hereinafter referred to as “phase 1”) sequencing
analysis revealed only previously reported SNPs in the
OXT gene. In OXTR, we found three rare variants
(V172A, L206V, W203R, Table 3) that were not present
in public databases at the time of the data analysis. Of
note, the mutant allele at codon 206 was always
detected together with that at codon 172, indicative of a
rare double-mutant haplotype, while the V172A rare al-
lele was identified both on its own and together with
the L206V rare allele. We found that all the missense
variants identified were located in one high-yield amplicon
of OXTR, which corresponds to exon 3, and therefore
attempted to replicate these phase 1 sequencing results
in more individuals.
Phase 2 (replication) sequencing was performed on pre-
term cases and term controls from the U.S., Argentina,
Finland, and Denmark (Table 1). The OXTR variants iden-
tified and their locations in the receptor are shown in
Table 3 and Figure 3, respectively. The F284L mutation
(rs201783860), which was detected in one case mother
from the U.S., was also transmitted to the infant. In a
well-characterized cohort of case (≤36 weeks gestation,
N=723) and control (40 weeks gestation, N=920) mothers
selected from the DNBC Study [16], we found three novel
variants, including A11T, V211L, and A247A (Table 3).
All but four (V45L, V211L, A247A, and G252A) rarecoding variants identified in phase 1 and 2 studies were
found in cases only.
To gain a more complete understanding of the spectrum
of genetic variation in exon 3 of OXTR and the importance
of the identified OXTR rare variants in predisposition to
PTB, we examined recent data from the 1000 Genomes
Project (1000GP) [28,29] and the NHLBI GO Exome
Sequencing Project (NHLBI_ESP) [30] (see Methods for
more details). A list of coding variants in exon 3 of OXTR
reported in the two databases is shown in Additional file 1.
We compared this list with our sequencing results and
found 5 variants (V45L, V172A, L206V, G252A, and
V281M) overlapping with our data in individuals of
European origin. It was particularly noted that two
(V172A and L206V) of the 5 variants occur at much
higher frequencies in African Americans (MAF: V172A,
5.52% and L206V, 1.84%) than in European Americans
(MAF: V172A, 0.01% and L206V, 0.01%). It would be in-
teresting to explore if these variants play a role in prema-
turity, given that about 10% of normal individuals whose
sequences are catalogued in the databases are expected to
be preterm and that PTB rates are higher in African
Americans than in whites [32]. In addition, we found 4
rare variants (A11T, P108A, W203R, and F284L) that are
present exclusively in our cases with PTB. Importantly,
three of them were predicted to have functional effects by
PolyPhen [33] and SIFT [34] (Table 4), suggesting that
they are potentially etiologic.
Association analysis of all rare coding variants identi-
fied by phase 1 and 2 sequencing showed no significant
results – either when the variants were tested individu-
ally or when all missense variants were combined and
analyzed together (Table 5).
We further extended our analysis on Danish mothers,
in particular, and performed regression analyses to more
precisely define the effects of OXTR genetic variation on
Table 3 Summary of all OXTR coding variants detected by resequencing in the present study
Position1 Nucleotide
variation2
Amino acid
substitution
Domain
location
dbSNP ID Sequencing analysis3 Number of variant carriers4
Mother Infant
Case Control Case Control
8809843 +31C>T A11T END Case–control (P2) 1 (D) 0 0 0
8809741 +133C>A V45L TMD 1 Case–control (P2) 0 2 (D) 0 0
8809552 +322G>C P108A ECL 1 rs202138705 Case–control (P2), MT 1 (F) 0 0 0
8809446 +428T>C Q143R ICL 2 MT
8809359 +515A>G V172A TMD 4 rs115324487 Case–control (P1 and P2), MT 7 (A, U) 0 5 (A, U) 0
8809267 +607A>G W203R ECL 2 rs200498154 Case–control (P1) 0 0 1 (U) 0
8809258 +616G>C L206V5 TMD 5 rs150746704 Case–control (P1 and P2) 2 (U) 0 3 (A, U) 0
8809243 +631C>A V211L TMD 5 Case–control (P2) 1 (D) 1 (D) 0 0
8809222 +652C>T A218T TMD 5 rs4686302 All
8809184 +690G>A N230N ICL 3 rs237902 All
8809162 +712C>T A238T ICL 3 rs61740241 All
8809150 +724C>G E242Q ICL 3 MT
8809133 +741C>T A247A ICL 3 Case–control (P2) 2 (D) 1 (D) 0 0
8809119 +755C>G G252A ICL 3 rs151141371 Case–control (P2), MT 3 (D) 2 (D, F) 0 0
8809033 +841C>T V281M TMD 6 rs144814761 Case–control (P2) 1 (D) 0 0 0
8809024 +850A>G F284L6 TMD 6 rs201783860 Case–control (P2) 1 (U) 0 0 0
1Position (on chromosome 3) according to NCBI Build 37.3 GRCh37.p5 assembly.
2Nucleotide numbering: +1 is the A of the ATG translation initiation codon.
3Sequencing analysis in which the variant indicated was detected. See text for further details.
4Counts of common variant (A218T, N230N, and A238T) carriers are not shown. Counts from maternal triad analysis were not included: P108A, Q143R, V172A,
E242Q, and G252A were identified each in one family. Letter in parentheses is a population code: A: Argentina, D: Denmark, F: Finland, and U: U.S.
5Always found together with V172A.
6Identified in a twin case and not considered for formal association analysis.
ECL: extracellular loop, END: extracellular N-terminal domain, ICL: intracellular loop, TMD: transmembrane domain, P1: phase 1, P2: phase 2, MT: maternal triad.
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http://www.biomedcentral.com/1471-2350/14/77GA. We modeled the effects of all coding variants (both
common and rare) identified by sequencing on GA
treated as either a continuous (in weeks) or categorical
(preterm, ≤36 weeks; and term, 40 weeks) variable. How-
ever, no results were found to be significant in both ana-
lyses (Additional file 2).
Maternal OXTR sequence variation and susceptibility to PTB
To address in more depth the importance of maternal
genetic effects on the risk of PTB, we extended the re-
sults obtained from the study of Danish mothers by
performing sequence analysis of OXTR in maternal triadsFigure 3 Schematic representation of OXTR gene structure and
location of all coding variants identified by sequencing. Note
that all the variants were found in exon 3 (indicated by an asterisk)
that encodes 6 of 7 transmembrane domains of the receptor.created from 309 pedigrees from the U.S., Argentina,
and Denmark (Table 1) as well as in a small group of
Caucasian patients from Iowa consisting of case (n=71)
and control (n=64) mothers. Each maternal triad consisted
of a mother of a preterm infant with GA between 23
and 36 weeks and her parents (grandmother-grandfather-
mother), and we examined the transmission of OXTR vari-
ant alleles from maternal grandparents to the mothers
of affected infants using the transmission disequilibrium
test (TDT).
Among 8 coding variants identified by sequencing,
two (Q143R and E242Q) were previously unreported
novel variants (Table 3). Our TDT analysis did not re-
veal any significant association either when we exam-
ined all GAs together (Figure 4) or three subgroups
(early, middle, and late) stratified by GA. (Of note, due
to very low frequencies of rare variant minor alleles,
complete results were available only for 3 SNPs
(rs4686302, rs237902, and rs61740241) with more than
10 informative families.) However, when we performed
a stratified analysis for the U.S. triads (N=109) using
five-week sliding windows of GA, rs4686302 and
rs237902 were found to be significant for the 24–28 and
28–32 week groups and the 27–31 and 28–32 week
groups, respectively (Figure 4).
Table 4 In silico prediction of functional significance of OXTR missense variants identified by resequencing
Amino acid
change
PolyPhen SIFT
Prediction PSIC score difference Prediction Tolerance index
A11T Benign N/A Tolerated 0.44
V45L Benign N/A Tolerated 0.11
P108A* Probably damaging 2.243 Affect protein function 0.04
Q143R Benign 0.286 Tolerated 0.67
V172A Benign 0.820 Tolerated 0.37
W203R* Probably damaging 4.115 Affect protein function 0.00
L206V Benign 0.319 Tolerated 0.41
V211L Benign N/A Tolerated 0.41
A218T Benign 0.324 Tolerated 0.36
A238T Benign 0.330 Tolerated 0.59
E242Q Benign 0.740 Tolerated 0.59
G252A Benign 0.278 Tolerated 0.74
V281M* Probably damaging 2.013 Affect protein function 0.00
F284L* Probably damaging 2.208 Affect protein function 0.01
*Amino acid substitutions with predicted deleterious effects.
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control study (71 case and 64 control mothers). We first
developed logistic regression models to predict case/con-
trol status, and found that the model containing the two
polymorphisms rs4686302 and rs237902 best explains
case–control status (p=0.04, 0.05, respectively, R2=0.062)
(Table 6). Next, linear regression analyses were performed
to predict GA and BW. As demonstrated in Table 6,
the models containing (rs237902 + rs61740241) andTable 5 Association of OXTR rare coding variants with preterm
Position1 Rare
allele
Amino acid
substitution
dbSNP ID
Denmark2
N=723 (case) / 920 (c
Mother
8809843 T A11T 0.43
8809741 A V45L 0.51
8809552 C P108A rs202138705 -
8809359 G V172A rs115324487 -
8809267 G W203R rs200498154 -
8809258 C L206V rs150746704 -
8809243 A V211L 1.00
8809133 T A247A 1.00
8809119 G G252A rs151141371 0.33
8809033 T V281M rs144814761 0.44
All missense variants combined4 0.35
1Position (on chromosome 3) according to NCBI Build 37.3 GRCh37.p5 assembly.
2Subjects include mothers only.
3Subjects include both mothers and infants.
4All missense variants detected in each population were combined together for ana
- Variant not found in the population indicated.(rs4686302 + rs61740241) were best at predicting lower
GA (p=0.03, 0.04, R2=0.055) and lower BW (p=0.008,
0.01, R2=0.074), respectively. The results indicate that 2
SNPs significantly explain 5.5% of the variation in GA
and 7.3% of the variation in BW with rs61740241 in a
slightly more supportive role to the other SNP. The
SNPs that best predict case–control status are identical
to the SNPs involved as the main predictors of GA in
weeks and BW in grams.birth in Danish, Finnish, and U.S. populations
Population
Finland2 U.S.3
ontrol) N=105 (case) / 95 (control) N=443 (case) / 34 (control)
Mother Mother Infant
- - -
- - -
1.00 - -
- 1.00 1.00
- N/A N/A
- 1.00 1.00
- - -
- - -
0.43 - -
- - -
1.00 1.00 1.00
lysis.
Figure 4 Results of TDT analysis for three OXTR coding SNPs
detected in U.S. maternal triads by sequencing. Data on three
OXTR SNPs (rs4686302, rs237902, and rs61740241) were analyzed on
all GAs or five-week sliding window-stratified subgroups. Note that
no data were available for some GA subgroups due to the lack of a
sufficient number of informative families.
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polymorphisms
We performed in vitro functional studies on the afore-
mentioned three OXTR missense mutations (P108A,
W203R, and F284L) that were uniquely identified in our
PTB cases and predicted as deleterious by PolyPhen [33]
and SIFT [34] (Table 4). We first tested the ligand-
binding properties of the mutant receptors, using transi-
ently transfected COS-7 cells. To this end, the level of
[3H]OXT binding was assessed in empty vector-, wild-
type or mutant OXTR-expressing cells in the presence
or absence of excess unlabeled OXT. The specific bind-
ing of [3H]OXT to intact transfected cells was defined asTable 6 Results of regression analyses of OXTR coding varian
(A) Model1 n (case, control)
rs4686302 (A218T) 60, 60
rs237902 (N230N) 60, 60
rs61740241 (A238T) 60, 59
rs4686302 (A218T) + rs237902 (N230N)2 60, 60
(B) Model1 n
rs4686302 (A218T) 120
rs237902 (N230N) 120
rs61740241 (A238T) 119
rs237902 (N230N) + rs61740241 (A238T)4 120
rs4686302 (A218T) + rs61740241 (A238T)5 120
1(A) Logistic regression analysis to predict case/control status and (B) Linear regress
2The most parsimonious model for predicting case/control status.
3 rs4686302 OR=2.861 (1.041, 7.859) and rs237902 OR=1.803 (0.993, 3.273).
4The most parsimonious model for predicting gestational age.
5The most parsimonious model for predicting birth weight.the difference between total and non-specific binding.
We initially observed a considerable decrease in specific
binding in cells transfected with the mutant plasmids,
compared to those transfected with the wild-type plas-
mid. Because this could be a reflection of lower expres-
sion of the mutant receptor proteins, we attempted to
increase their expression levels using twice more plas-
mid DNA (4 μg per well). However, the mean binding
levels (in cpm/million cells) in each transfection group
hardly varied. Based on this observation, we combined
data from all experiments performed, regardless of the
amount of transfected DNA. As shown in Figure 5, two
of the three mutations (P108A and W203R) tested
exhibited a statistically significant reduction in [3H]OXT
binding. For the W203R mutation, there was nearly
complete abolishment of specific binding. Our results
suggest that these mutations may cause either reduced
receptor expression or ligand affinity, leading to im-
paired ligand binding.
To gain insight into whether the missense mutations
affect receptor signaling, OXT-stimulated inositol phos-
phate (InsP) production by wild-type and mutant OXTRs
was evaluated. Figure 6A summarizes the results obtained.
The accumulation of [3H]InsPs increased more than two-
fold in response to oxytocin in wild-type OXTR-
expressing cells, while this increase was not observed in
mutant plasmid- and empty vector-transfected cells. In
addition, basal (unstimulated) levels of inositol phosphates
were almost indistinguishable between wild-type OXTR
and the three mutant receptors (Figure 6B), suggesting
that the mutant receptors are unlikely to be constitutively
active. Taken together, these data indicate that the exam-
ined mutations may have no effect on the coupling of the
receptor to the second messenger signaling system.ts detected in Iowa case and control mothers
P R2
0.19 0.020
0.24 0.015
0.75 0.001
0.04, 0.053 0.062
Gestational age Birth weight
P R2 P R2
0.14 0.019 0.08 0.025
0.23 0.022 0.17 0.016
0.77 0.001 0.53 0.003
0.03, 0.04 0.055 N/A N/A
N/A N/A 0.008, 0.01 0.074
ion analysis to predict gestational age and birth weight.
Figure 5 Comparison of specific [3H]OXT binding to wild-type
and mutant oxytocin receptors. COS-7 cells were transiently
transfected with empty pcDNA3.1 vector and vectors encoding
wild-type and mutant OXTRs, and were exposed to 50 nM [3H]OXT
in the absence and presence of 20 μM unlabeled oxytocin. Specific
binding was determined as described in Methods. Statistical
significance of differences in [3H]OXT specific binding between wild-
type- and mutant-transfected cells was determined using one-way
ANOVA followed by Dunnett's test. Data presented are mean in
cpm/106 cells ± SEM of multiple experiments performed in
duplicate. * p<0.05.
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Pregnancy and parturition involve an intricate biochemical
and molecular interplay between mother and fetus [10].
The study of PTB has been hampered by incomplete
knowledge of these complex, time-varying processes, and
an investigation of static makers like sequence variants
may serve as one way to predict the risk of PTB.Figure 6 Inositol phosphate (InsP) accumulation in COS-7 cells transie
cells prelabeled with myo-[3H]inositol were treated with buffer alone or wi
accumulation was measured as described in Methods. (A) Oxytocin-stimula
with unstimulated (basal) InsP levels. (B) Comparison of basal levels of InsP
the unstimulated (basal) InsP levels in cells expressing wild-type receptor. DIn this study, we used a candidate gene approach to
better understand genetic factors contributing to PTB.
Previous studies have identified some polymorphisms
suggestively associated with PTB, but with a focus
mostly on immune-related and inflammatory genes such
as interleukin 1 receptor antagonist (IL1RN), interferon
gamma (IFNG), and coagulation factor II (F2) [15]. The
present study was undertaken to explore the contribu-
tion of genetic variations in another functionally relevant
pathway, the oxytocin pathway to the etiology of PTB,
given the important role of constituents of the pathway
in labor and parturition.
Our analysis of fourteen SNPs in OXT, OXTR, and
LNPEP revealed no evidence of fetal genetic effects on
PTB. However, the analysis of maternal genetic effects
performed all GA cases identified three SNPs in LNPEP
that correlate with prematurity when not corrected for
multiple comparisons. This finding is in line with the re-
sults of recent studies demonstrating that the maternal
genome has a major impact on the risk of prematurity
[35,36] and can be considered hypothesis generating for
further investigations in the role of LNPEP in preterm
labor (PTL).
Ishii et al. [37] reported that in LNPEP knockout mice,
an increased sensitivity to OXT is observed and pregnancy
duration is significantly shortened, providing functional
evidence supporting our genetic data. It was noted that
the same three LNPEP SNPs showing suggestive associ-
ation in the analysis of all GAs remained significant in the
GA-stratified analysis, further supporting the importance
of these SNPs. The activity of LNPEP is known to grad-
ually increase during late pregnancy and reach a very
high level at 11 days before the onset of labor [37].
Interestingly, in our five-week sliding window analysis
for maternal effects, the three SNPs were found to be sig-
nificant in late GA groups (30–34, 31–35, and 32–36 weekntly transfected with wild-type and mutant OXTRs. Transfected
th 100 nM oxytocin. After one hour of incubation, inositol phosphate
ted InsP accumulation. Results are presented as fold change compared
accumulation in transfected cells. Results are presented as the ratio to
ata are mean ± SEM of multiple experiments performed in duplicate.
Kim et al. BMC Medical Genetics 2013, 14:77 Page 12 of 14
http://www.biomedcentral.com/1471-2350/14/77groups) although there was an additional significant SNP
(rs13175726) detected for the 26–30 week group. Pending
replication with larger samples, we postulate that these
polymorphisms, all of which are non-coding SNPs, may
serve as regulatory elements for the LNPEP gene rather
than having a direct functional effect.
We screened the OXTR gene for rare genetic variation
by resequencing and identified both previously reported
and unreported rare variants in exon 3, which is highly
conserved across species (Additional file 3). The variants
identified were not found to be significantly associated
with PTB, but these results should be interpreted cau-
tiously because of the small sample size and the paucity
of sequencing data on controls, especially those from
Argentina and the U.S.
Our analysis comparing the rare variants identified by
sequencing with those catalogued in the public data-
bases demonstrates that some of the rare variants may
be of etiologic importance. The observation that three
(P108A, W203R, and F284L) of the four rare missense
variants not found in either the 1000GP [28,29] or the
NHLBI_ESP [30] data were predicted to affect the func-
tion of the receptor protein particularly merits further
attention. These results suggest that rare OXTR coding
variants appear to make some contribution to the gen-
etic risk of prematurity, but larger studies will be
needed to measure their combined as well as individual
impact more accurately and determine the diagnostic or
therapeutic relevance of the findings.
We studied the role of maternal OXTR genotype in
PTB in more depth using maternal grandparent-mother
triads. Transmission disequilibrium analysis revealed no
significant transmission distortion of the OXTR coding
variants examined when the analysis was performed on
all GA cases or stratified into 3 GA groups. However,
two missense SNPs (rs4686302 and rs237902) showed
nominal associations in the U.S. triads for the sliding
window GA subgroups primarily involving 24–32 weeks
of gestation. These results suggest GA-specific effects of
maternal genotypes of these OXTR SNPs on susceptibil-
ity to PTB.
We characterized the effects of three mutations of po-
tential functional significance with in vitro assays. Our
radioligand binding assay revealed that P108A and
W203R mutant-transfected cells display significantly di-
minished levels of [3H]OXT specific binding, compared
to wild-type-transfected cells. Although it should be fur-
ther clarified if the mutations affect OXTR protein ex-
pression, ligand binding affinity, or both, our results
indicate the importance of these residues in receptor
function and support previous findings that the first and
second extracellular loops of OXTR, where P108 and
W203 residues, respectively, are located, are important
for agonist binding and selectivity [38]. Despite theirimportant biological effects, it is yet unclear how the mu-
tations may contribute to the disease as it is counterintui-
tive that attenuated OXT signaling leads to PTB. However,
it is possible that the variants may act indirectly to stimu-
late uterine contractions. Given that the regulation of
OXTR function is dependent on steroids such as estradiol,
progesterone, and its metabolites [39-41], it is probable
that the mutations may affect receptor-hormone inter-
action in a way that interferes with the timely onset of
labor.
Another mutation, F284L, also exhibited a reduced level
of specific binding, but the result did not quite reach
statistical significance. An earlier mutagenesis study has
shown that when two transmembrane residues Y209 and
F284 are mutated to F and Y residues, respectively, argin-
ine vasopressin (AVP), a partial agonist of the OXTR, be-
comes a full agonist [8,42]. The finding indicates that
these residues may be critical for modulation of the recep-
tor response to AVP. Given the uterotonic action of AVP
[43], an investigation into the sensitivity of the F284 as
well as the other two mutants to other agonists like AVP
could possibly provide an explanation about the patho-
genic effects of those mutations.
Our study has certain limitations. First of all, the sam-
ple size of our association study may not be large
enough to provide sufficient statistical power for the
analysis of rare variants with small effects. Second, the
functional assays were not carried out in a cellular con-
text relevant to address mechanisms of PTB. The func-
tional role of the identified OXTR mutations should be
determined using physiologically more relevant cell
types such as uterine myometrial cells. In addition, we
only focused on the InsP pathway to examine the down-
stream effects of the OXTR mutations. We did not ob-
serve any significant difference in OXT-induced InsP
production between wild type and mutant receptor-
expressing cells, and it is possible that their effects are
mediated through other signal transduction pathway(s).
Therefore, it would be important to examine the impact
of the mutations on different biologic pathways like the
MAP kinase pathway [44].
Conclusions
This study provides preliminary evidence for an associ-
ation between maternal common polymorphisms in the
LNPEP gene and the risk of PTB. In addition, we found
that maternal OXTR missense SNPs rs4686302 and
rs237902 may have gestational age-dependent effects on
prematurity. These observations support that sequence
variants in maternal genes may have a primary role in
susceptibility to PTB. Most of the OXTR rare variants
identified do not appear to significantly contribute to the
risk of PTB. However, the importance of the non-
synonymous rare variants shown to cause altered ligand
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http://www.biomedcentral.com/1471-2350/14/77binding warrants further investigation. Future genetic
studies with larger sample sizes are needed to confirm
the findings of the association analyses performed in the
present study. Additional functional studies may provide
more detailed insight into the precise physiological ef-
fects and clinical significance of the genetic variants
identified and ultimately, accelerate translation of such
findings into genetic-based diagnostic and therapeutic
applications.
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